11th Feb 2020 12:00
(Alliance News) - Hemogenyx Pharma PLC on Tuesday said US Patent & Trademark Office has approved a patent application entitled postnatal hemogenic endothelial cells and their isolation & use.
Postnatal hemogenic endothelial cells are a special sub-class of progenitor stem cell that generate hematopoietic stem cells. This makes them a "perfect" candidate for patient-specific, or autologous, bone marrow transplantations.
These cells were posited and discovered by Hemogenyx Co-Founder & Chief Executive Vladislav Sandler while working at Cornell University. The patent application was filed in 2014, and Hemogenyx was granted a world-wide exclusive sub-licensable licence for the patent by Cornell in 2015.
If fully developed, the postnatal hemogenic endothelial cell technology can provide a new form of blood stem cell replacement therapy and potentially eliminate the principal problems that arise from the existing forms of treatment, Hemogenyx said.
The London-headquartered immunotherapies company explained that postnatal hemogenic endothelial cell-based technology presents some "important" advantages due to the fact that these cells are a naturally occurring cell type found in adult and postnatal mammalian tissues. They can be isolated and do not require heavy manipulation before use, Hemogenyx highlighted.
"The issue of this patent is significant for the company as it solidifies and protects Hemogenyx's position as a leader in the area of cell therapy and helps to place postnatal hemogenic endothelial cells at the foundation of the development of novel methods of combatting blood cancers and auto-immune diseases," said Sandler.
Hemogenyx shares were trading 0.5% higher in London on Tuesday at 2.01 pence each.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hemogenyx